A blog about chemistry, drug development, science, and technology
Seems Representative Henry Waxman (D, CA) wants to hear from the following companies about the following drugs for the following reasons:
Lilly: Zyprexa (bipolar). Inappropriate promotion for off-label use
AstraZeneca: Seroquel (schizophrenia). Inappropriate marketing
Boston Scientific: drug coated stents. Safety and off-label use
Cordis: drug coated stents. Safety and off-label use
Cephalon: Actiq (narcotic lollipop) and Fentora (narcotic lozenge). Inappropriate marketing
Here are the letters that were sent.
WaxmanLilly.pdf
WaxmanAZ.pdf
WaxmanBoston.pdf
WaxmanCordis.pdf
WaxmanCephalon.pdf
The longest letter went to Cephalon over their narcotic products . All the letters are asking for a long list of items to be provided covering clinical trials, audits, presentations, training material, communication to healthcare providers and much more. It will be interesting to watch and see which cooperate and which may refuse to turn over the requested documents. For Cephalon and Actiq it is for data from 1997 to the present; almost 10 years of data.
Technorati Tags: Actiq, AstraZeneca, Boston Scientific, Cephalon, Cordis, Eli Lilly, Fentora, drug coated stents, Seroquel, Waxman, Zyprexa
Bookmark it with:
|
del.icio.us
|
Digg it
|
Furl
|
Simpy
|
Spurl
|
My Yahoo!
|
[powered by WordPress.]
QDIS: blogging about chemistry, drug development, science and technology.

By Category
Chemistry, science, and technology for the future.

35 queries. 1.073 seconds